<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="656">
  <stage>Registered</stage>
  <submitdate>25/08/2005</submitdate>
  <approvaldate>25/08/2005</approvaldate>
  <nctid>NCT00137995</nctid>
  <trial_identification>
    <studytitle>R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma</studytitle>
    <scientifictitle>Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CORAL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma, Large-Cell, Diffuse</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rituximab
Treatment: drugs - Etoposide
Treatment: drugs - Carboplatine
Treatment: drugs - Ifosfamide + Mesna
Treatment: drugs - Cisplatine
Treatment: drugs - Cytosine Arabinoside
Treatment: drugs - Dexamethasone
Treatment: surgery - Autologous Stem Cell Transplantation
Treatment: drugs - BCNU
Treatment: drugs - Etoposide
Treatment: drugs - Cytarabine
Treatment: drugs - Melphalan

Experimental: R-ICE - R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation

Experimental: R-DHAP - R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation


Treatment: drugs: Rituximab
375 mg/m² D-2/D1

Treatment: drugs: Etoposide
100 mg/m² D1-D2-D3

Treatment: drugs: Carboplatine
max 800mg D2

Treatment: drugs: Ifosfamide + Mesna
5 g/m² from D2 to D13

Treatment: drugs: Cisplatine
100 mg/m² from D1 to D13

Treatment: drugs: Cytosine Arabinoside
2000 mg/m²/12 h D2 D3

Treatment: drugs: Dexamethasone
40 mg From D1 to D4

Treatment: surgery: Autologous Stem Cell Transplantation


Treatment: drugs: BCNU
300mg/m² on D-6

Treatment: drugs: Etoposide
200 mg/m² from D-6 to D-3

Treatment: drugs: Cytarabine
100 mg/m² from D-6 to D-3

Treatment: drugs: Melphalan
140 mg/m² on D-2

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>MARR (mobilization adjusted response rate)</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>EFS (event free survival)</outcome>
      <timepoint>2 years post transplantation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression rate</outcome>
      <timepoint>2 years post transplantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>2 years post transplantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>2 years post transplantation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients with CD20-positive diffuse large B-cell lymphoma. Disease must be
             histologically proven in case of relapse or partial response.

          -  Aged 18 to 65 years

          -  First relapse after complete remission (CR), less than partial remission (PR) or
             partial response to first line treatment not achieving documented or confirmed
             complete remission.

          -  Eligible for transplant

          -  Previously treated with chemotherapy regimen containing anthracyclines with or without
             rituximab.

          -  ECOG performance status 0 to 2.

          -  Minimum life expectancy of 3 months.

          -  Signed written informed consent prior to randomization.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Burkitt, mantle-cell and T-cell lymphoma.

          -  CD20-negative diffuse large cell lymphoma

          -  Documented infection with HIV and hepatitis B virus [HBV] (in the absence of
             vaccination)

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Not previously treated with anthracycline-containing regimens

          -  Prior transplantation

          -  Contra-indication to any drug contained in the chemotherapy regimens.

          -  Any serious active disease or co-morbid condition (according to the investigator's
             decision and information provided in the Investigational Drug Brochure [IDB]).

          -  Poor renal function (creatinine level &gt; 150µmol/l or 1.5-2.0 x upper limit of normal
             [ULN]); poor hepatic function (total bilirubin level &gt; 30mmol/l [&gt; 1.5 x ULN],
             transaminases &gt; 2.5 maximum normal level) unless these abnormalities are related to
             the lymphoma; poor bone marrow reserve as defined by neutrophils &lt; 1.5G/l or platelets
             &lt; 100G/l, unless related to bone marrow infiltration.

          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma.

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Pregnant women

          -  Adult patients unable to provide informed consent because of intellectual impairment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>481</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Australian leukemia and lymphoma group - Sydney</hospital>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Yvoir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Lymphoma Study Association</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the efficacy and safety of induction
      therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of
      stem cells in patients with previously treated diffuse large B-cell lymphoma CD20.

      The goal is to detect a difference in mobilization adjusted response rate of 15% between
      R-ICE and R-DHAP.

      The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy
      after transplantation as measured by the event free survival.

      The goal is to obtain a 15% increase of event free survival at 2 years.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00137995</trialwebsite>
    <publication>Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998 Nov 15;92(10):3562-8.
Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004 May 15;103(10):3684-8. Epub 2004 Jan 22.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.
Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn JY, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H, Chauvin F. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998 Oct;16(10):3264-9.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christian Gisselbrecht</name>
      <address>Lymphoma Study Association</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>